Thermo Fisher hikes growth forecast, expects COVID-19 sales to top $3B in late 2020

The company forecasts significantly higher growth this year than it's posted in the past, despite suffering a slow first quarter due to early disruption from the pandemic.

By Nick Paul Taylor • Sept. 11, 2020

Quest raises 2020 revenue outlook to beat pre-coronavirus goal by 10%

Despite worries that summer coronavirus hotspots could reverse the recovery for routine testing, the lab network said base volumes grew faster than expected through August.

By Maria Rachal • Sept. 10, 2020

BD says its antigen test on par with Quidel's in head-to-head preprint study

The state of Maryland announced Thursday it bought 250,000 of the BD tests, which the company contends have shown equivalent performance to Quidel's despite a difference in earlier published sensitivity claims.

By Greg Slabodkin • Sept. 10, 2020

LabCorp, DiaSorin tests differentiate COVID-19, flu, RSV

The companies join test developers including Roche, Qiagen, BioFire Diagnostics and Novacyt in preparing combination tests to tackle the challenges of the upcoming influenza season.

By Susan Kelly • Sept. 9, 2020

Surgeries keep rising, buoying Wall Street's year-end medtech outlook

Jefferies reported a fourth consecutive week of growing hospital traffic, while Bank of America is "broadly bullish" on the medical devices sector as 2020 wraps up.

By Greg Slabodkin • Sept. 8, 2020

Roche COVID-19, flu combo test gets FDA emergency authorization

It is the fourth EUA for a diagnostic that detects and differentiates the viruses. However, the company claims to be the first commercial test that runs on fully automated high-throughput systems using a single sample.

By Greg Slabodkin • Sept. 4, 2020

NIH awards $129M to scale up US COVID-19 testing capacity

Illumina, Sonic Healthcare and PathGroup are among recipients of the funds with a goal to handle 454,000 tests a day. However, the country needs millions more daily tests above current levels. 

By Nick Paul Taylor • Sept. 3, 2020

Florida cuts ties with Quest after delayed reporting of 75K COVID-19 test results

Gov. Ron DeSantis ordered all Florida agencies to sever testing relationships with the lab giant, which apologized for the delay in getting data to state health authorities in the timely manner required by law.

By Susan Kelly • Sept. 2, 2020

HHS terminates Hamilton, Vyaire ventilator contracts

The Strategic National Stockpile now has an adequate supply of the devices, the agency said. The two companies will not deliver the additional 38,000 ventilators they'd planned by year's end.

By Greg Slabodkin • Sept. 2, 2020

Roche set to launch rival to Abbott's rapid COVID-19 antigen test

The diagnostics giant expects to make 40 million of the instrument-free tests a month when it launches in late September and more than double that by the end of 2020, but doesn't yet have emergency authorization from FDA.

By Nick Paul Taylor • Sept. 2, 2020

HHS backs COVID-19 antigen testing for nursing homes, preempting regional restrictions

Although some state and local authorities are concerned about the accuracy of such rapid diagnostics, sold by Abbott, BD and others, the move comes amid rising calls for their use to test large numbers of people.

By Nick Paul Taylor • Sept. 1, 2020

Philips lowers 2020 outlook as HHS nixes ventilator contract

The medtech received a "partial termination" notice and will not deliver 30,700 remaining ventilators to the Strategic National Stockpile, a month after a House panel called for a probe into the roughly $647 million contract.    

By Greg Slabodkin • Aug. 31, 2020

Comparisons of COVID-19 saliva, swab tests paint mixed picture

Study findings published the same day in the New England Journal of Medicine and Annals of Internal Medicine have conflicting messages on saliva tests, which FDA has greenlit from developers including Fluidigm and Phosphorus.

By Nick Paul Taylor • Aug. 31, 2020

Abbott gets $760M contract from HHS to deliver 150M antigen tests

The deal comes just one day after the company's antigen test received FDA emergency use authorization. BD, Quidel and LumiraDx previously got the agency's nod for their diagnostics.

By Greg Slabodkin • Aug. 28, 2020

With a one-year reprieve to EU's MDR, some procrastinate, others speed ahead

Industry is taking advantage of a long-sought delay to the regulation in different ways, but COVID-19's impact on notified body capacity, pace of information from lawmakers, and company resources are some confounding variables. 

By Maria Rachal • Aug. 26, 2020

Hospitals slam 'disturbing' CMS COVID-19 data reporting requirement

The rule also implements a CARES Act requirement that all laboratories conducting COVID-19 testing report results to HHS daily, with fines for labs that don't comply.

By Shannon Muchmore • Aug. 26, 2020

Medtronic's Martha teases focus shift on diabetes, robotics

After pandemic-driven delays to its soft tissue robot, the company also told investors it expects to file for a CE mark and a U.S. investigational device exemption in the first quarter of calendar year 2021.

By Maria Rachal • Aug. 25, 2020

Ex-Trump FDA chief rails against new HHS policy on lab developed tests

Scott Gottlieb took to Twitter on Saturday criticizing last week's decision by the administration that FDA will no longer require premarket review of LDTs. "FDA’s ability to protect public health could be challenged," he warned. 

By Greg Slabodkin • Aug. 24, 2020

Cold War law invoked for BD, Quidel to prioritize antigen test contracts

The Trump administration's use of the Defense Production Act comes amid rising demand for the tests that can be less accurate than traditional molecular diagnostics, but offer results within minutes.

By Nick Paul Taylor • Aug. 21, 2020

House panel demands HHS briefing on decision to nix premarket review for COVID-19 lab developed tests

On Thursday, Energy and Commerce Chairman Frank Pallone, D-N.J., insisted the department explain its "deeply concerning" decision to allow coronavirus LDTs to come to market without FDA review.

By Greg Slabodkin • Updated Aug. 21, 2020

LumiraDx lands FDA's third COVID-19 antigen test EUA, as demand for rapid diagnostics rises

William Blair analysts questioned the immediate impact from the nod to the relatively small medtech, and instead looked ahead to the next potential big player to enter the market: Abbott.

By Nick Paul Taylor • Aug. 20, 2020

Why it's taken Quest so long to clear its COVID-19 testing backlog

The lab giant trailed chief rival LabCorp in turnaround times for most of July, slowed down by geography and the makeup of its customer base. Quest finally caught up this week, reporting average test results in one to two days.

By Greg Slabodkin • Aug. 18, 2020

FEMA pitches voluntary DPA pact to bolster medical supply chain during pandemic

The Defense Production Act allows private companies to enter agreements with the government while avoiding antitrust liability. AdvaMed wants to participate but FEMA has not yet extended an invite.

By Greg Slabodkin • Aug. 18, 2020

Thermo Fisher COVID-19 test flagged for false positive and negative results

An FDA alert on Monday follows a quarter in which coronavirus-related products added $1.3 billion to the medtech's sales, and after it scored an HHS contract to provide processing instruments to labs.

By Nick Paul Taylor • Aug. 18, 2020

Abbott, Roche COVID-19 antibody tests may mislead on immunity, study suggests

The MD Anderson study is the latest to question the value of such tests and note the risk they may lead people to incorrectly believe they are immune from further infection.

By Greg Slabodkin • Aug. 17, 2020